HUTCHMED flaunts its Business and its portfolio’s potential at the R&D Updates Event

Announcement

HUTCHMED Limited highlighted its business updates and research and development initiatives showcased during the R&D updates event held on 31^st October 2025. The event witnessed HUTCHMED’s progress to date in bolstering immunology and innovative cancer treatments involving the presentation of its comprehensive antibody-targeted therapy conjugate (ATTC) platform. Alongside, the company provided an update on late-stage streamline candidates.

The Head of R&D and Chief Medical Officer of HUTCHMED, Dr Michael Shi, said, “Our dedication to shaping innovative therapies shows HUTCHMED’s mission to recognise crucial unmet needs in immunology and oncology. The ATTC platform’s capabilities to demonstrate oncology merged with our collaboration strategy and comprehensive pipeline rank us to serve effective, transformative immunology and cancer treatments to the patient population across the globe.”

HUTCHMED’S excellence

Under the commendable approach of precision oncology through the ATTC platform, unifying monoclonal antibodies, including exclusive small-molecule inhibitor payloads to serve dual mechanisms of action, HUTCHMED’s ATTC candidate, ‘HMPL-A251’, a PAM-HER2 ATTC, showed excellence through its preclinical data. The preclinical data for HMPL-A251 were showcased at the 2025 AACR-NCI-EORTC International Conference on Cancer Therapeutics and Molecular Targets.

The HMPL-A251 elaborated HER2-dependent antitumor activity with the capable inhibition of HER2-positive tumor cell increase, excluding or including PAM pathway alterations, with the average reduction activity noted in HER2-low, PAM-altered lines. Overall, the HMPL-A251 discovered a powerful bystander effect, affecting HER2-null cells when co-developed with HER2-positive cells.

Fully empowered with these positive and satisfying preclinical results in HER2-low and HER2-positive models, regardless of alterations, HUTCHMED intends to advance HMPL-A251 into a valuable clinical development, nearly to begin in late 2025 with a data-fueled strategy. The primary studies will examine the candidate selection procedure across numerous cancer types involving diverse PAM and HER2 alteration statuses.

Besides the potential of the ATTC platform and its HUTCHMED candidate, the R&D updates focused on a few late-stage programs. The Fruquintinib FRUSICA-2 Study’s data from the phase 3 trial of fruquintinib in merger with sintilimab for second-line renal cell carcinoma was also spotlighted at the ESMO Congress 2025. The key program also includes savolitinib registration studies, with its completion for the SANOVO China phase 3 study in primary EGFR-mutated non-small cell lung cancer (NSCLC) with MET overexpression.

Additionally, the studies for surufatinib for pancreatic cancer and sovleplenib for wAIHA and ITP preparations for its resubmission of the new drug application have also been recorded in the R&D Updates Event.